BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors by Reisländer, T, Lombardi, E, Groelly, F, Miar, A, Porru, M, Di Vito, S, Wright, B, Lockstone, H, Biroccio, A, Harris, A, Londoño-Vallejo, A, Tarsounas, M

Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours by Groelly, FJ, Porru, M, Zimmer, J, Benainous, H, De Visser, Y, Kosova, AA, Di Vito, S, Serra, V, Ryan, A, Leonetti, C, Bruna, A, Biroccio, A, Tarsounas, M

Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds by Zimmer, J, Tacconi, E, Folio, C, Badie, S, Porru, M, Klare, K, Tumiati, M, Markkanen, E, Halder, S, Ryan, A, Jackson, S, Ramadan, K, Kuznetsov, S, Biroccio, A, Sale, J, Tarsounas, M

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity. by Tacconi, E, Lai, X, Folio, C, Porru, M, Zonderland, G, Badie, S, Michl, J, Sechi, I, Rogier, M, Matía García, V, Batra, A, Rueda, O, Bouwman, P, Jonkers, J, Ryan, A, Reina-San-Martin, B, Hui, J, Tang, N, Bruna, A, Biroccio, A, Tarsounas, M

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance by Tacconi, E, Badie, S, De Gregoriis, G, Reisländer, T, Lai, X, Porru, M, Folio, C, Moore, J, Kopp, A, Baguña Torres, J, Sneddon, D, Green, M, Dedic, S, Lee, J, Batra, A, Rueda, O, Bruna, A, Leonetti, C, Caldas, C, Cornelissen, B, Brino, L, Ryan, A, Biroccio, A, Tarsounas, M